This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gamida Cell (GMDA) Jumps: Stock Rises 8.4%
by Zacks Equity Research
Gamida Cell (GMDA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Kindred Shares Up on Expansion of Agreement With Vaxart
by Zacks Equity Research
Kindred (KIN) expands an agreement with Vaxart for the manufacturing of the latter's oral vaccine for COVID-19 and other vaccine candidates.
Alexion (ALXN) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Iovance Stock Down on Delay in Filing for Melanoma Candidate
by Zacks Equity Research
Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.
Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint
by Zacks Equity Research
Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.
Vir Biotechnology (VIR) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Vir Biotechnology (VIR) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
Regeneron (REGN) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Regeneron (REGN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EBS) Outperforming Other Medical Stocks This Year?
AMAG (AMAG) to be Acquired by Covis Group for $647 Million
by Zacks Equity Research
AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.
bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA
by Zacks Equity Research
bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.
Cytokinetics (CYTK) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Cytokinetics (CYTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Galapagos Begins Dosing With GLPG3970 in Psoriasis Study
by Zacks Equity Research
Galapagos (GLPG) doses the first patient in an early-stage study on its Toledo compound GLPG3970 for treating psoriasis. The same is also being studied for ulcerative colitis and rheumatoid arthritis.
4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
Aerie to Initiate Phase IIb Study for Dry Eye Treatment
by Zacks Equity Research
The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.
Spero Therapeutics (SPRO) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
Spero Therapeutics (SPRO) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Aurinia Completes Final Patient Treatment in Dry Eye Study
by Zacks Equity Research
Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
by Zacks Equity Research
Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.
LogicBio Therapeutics (LOGC) Jumps: Stock Rises 6.1%
by Zacks Equity Research
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.
Alexion's Ultomiris Gets Approval in Japan for Rare Disease
by Zacks Equity Research
Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.
Blueprint Medicines' Gist Drug Ayvakyt Gets EU Approval
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V mutation.
Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants
by Zacks Equity Research
Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.
Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.
Pfizer Seeks Xalkori's Label Expansion, Gets Priority Review
by Zacks Equity Research
Pfizer's (PFE) sNDA seeking label expansion of lung cancer drug, Xalkori, for a hematologic indication gets priority review from the FDA.
9 Meters Biopharma (NMTR) in Focus: Stock Moves 5.8% Higher
by Zacks Equity Research
9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.